California's Second District Court of Appeal recently established a bright-line rule when it held that a lawyer's membership in the ADR provider deciding his case must be disclosed to the other side.

The relationship between a primary and excess insurance carrier within the context of a catastrophic medical malpractice litigation is fraught with possible pitfalls.

Columns & Departments

A look at a recent case in which the DOJ leveraged FIRREA.

In-depth analysis of a recent key ruling.

Given the DOJ's aggressive use of asset forfeitures, including higher-value forfeitures, counsel should be prepared to seek <i>Monsanto</i> hearings.

Features

While there have been high-profile setbacks to be sure, there is little reason to expect FCPA enforcement actions ' characterized by some as a tool in the war on terror ' to decline.

Features

The Department of Justice (DOJ) and Securities Exchange Commission's (SEC) Guide to the U.S. Foreign Corrupt Practices Act (FCPA) demonstrates, if there were any doubt, the importance of timely and effective FCPA remediation.

The Food and Drug Administration (FDA) provides some protection to drug companies regarding adverse event reports by allowing a disclaimer statement about liability. However, this is not a blanket defense against other potential liability exposure.